Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial

Lynda Stranix-Chibanda, Camlin Tierney, Dorothy Sebikari, Jim Aizire, Sufia Dadabhai, Admire Zanga, Cynthia Mukwasi-Kahari, Tichaona Vhembo, Avy Violari, Gerard Theron, Dhayandre Moodley, Kathleen George, Bo Fan, Markus J Sommer, Renee Browning, Lynne M Mofenson, John Shepherd, Bryan Nelson, Mary Glenn Fowler, George K Siberry, PROMISE P1084s study team, Lynda Stranix-Chibanda, Camlin Tierney, Dorothy Sebikari, Jim Aizire, Sufia Dadabhai, Admire Zanga, Cynthia Mukwasi-Kahari, Tichaona Vhembo, Avy Violari, Gerard Theron, Dhayandre Moodley, Kathleen George, Bo Fan, Markus J Sommer, Renee Browning, Lynne M Mofenson, John Shepherd, Bryan Nelson, Mary Glenn Fowler, George K Siberry, PROMISE P1084s study team

Abstract

Objectives: We set out to evaluate the effect of postnatal exposure to tenofovir-containing antiretroviral therapy on bone mineral density among breastfeeding women living with HIV.

Design: IMPAACT P1084s is a sub-study of the PROMISE randomized trial conducted in four African countries (ClinicalTrials.gov number NCT01066858).

Methods: IMPAACT P1084s enrolled eligible mother-infant pairs previously randomised in the PROMISE trial at one week after delivery to receive either maternal antiretroviral therapy (Tenofovir disoproxil fumarate / Emtricitabine + Lopinavir/ritonavir-maternal TDF-ART) or administer infant nevirapine, with no maternal antiretroviral therapy, to prevent breastmilk HIV transmission. Maternal lumbar spine and hip bone mineral density were measured using dual-energy x-ray absorptiometry (DXA) at postpartum weeks 1 and 74. We studied the effect of the postpartum randomization on percent change in maternal bone mineral density in an intention-to-treat analysis with a t-test; mean and 95% confidence interval (95%CI) are presented.

Results: Among 398/400 women included in this analysis, baseline age, body-mass index, CD4 count, mean bone mineral density and alcohol use were comparable between study arms. On average, maternal lumbar spine bone mineral density declined significantly through week 74 in the maternal TDF-ART compared to the infant nevirapine arm; mean difference (95%CI) -2.86 (-4.03, -1.70) percentage points (p-value <0.001). Similarly, maternal hip bone mineral density declined significantly more through week 74 in the maternal TDF-ART compared to the infant nevirapine arm; mean difference -2.29% (-3.20, -1.39) (p-value <0.001). Adjusting for covariates did not change the treatment effect.

Conclusions: Bone mineral density decline through week 74 postpartum was greater among breastfeeding HIV-infected women randomized to receive maternal TDF-ART during breastfeeding compared to those mothers whose infants received nevirapine prophylaxis.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. CONSORT flow diagram.
Fig 1. CONSORT flow diagram.
Fig 2. Percent change in bone mineral…
Fig 2. Percent change in bone mineral density from postpartum week 1 to week 74 at spine and hip.
Data points and the distributions are summarized with violin plots. Each violin plot presents density, along with horizontal lines indicating quartiles, a red circle for the median and a diamond for the mean (with whiskers for the 95% CI). Individual data points are superimposed on the violin plot.
Fig 3
Fig 3
Percent change to week 74 in (A) spine BMD (primary outcome measure) and (B) hip BMD: maternal TDF-ART vs. iNVP treatment effect modification by covariate.

References

    1. Kalkwarf H. and Specker B., “Bone mineral changes during pregnancy and lactation,” Endocrine, vol. 17, no. 1, pp. 49–53, February 2002, 10.1385/ENDO:17:1:49
    1. Kovacs C. S., “Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery,” Physiol. Rev., vol. 96, no. 2, pp. 449–547, February 2016, 10.1152/physrev.00027.2015
    1. Chitu-Tisu C.-E., Barbu E.-C., Lazar M., Ion D. A., and Anca I., “Original article Low bone mineral density and associated risk factors in HIV-infected patients,” GERMS, vol. 6, no. 2, pp. 50–59, 2016. 10.11599/germs.2016.1089
    1. Mondy K. et al., “Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.,” Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 36, no. 4, pp. 482–490, 2003, 10.1086/367569
    1. Kooij K. W. et al., “Low Bone Mineral Density in Patients With Well-Suppressed HIV Infection: Association With Body Weight, Smoking, and Prior Advanced HIV Disease,” Ournal Infect. Dis., vol. 211, pp. 539–548, 2015, 10.1093/infdis/jiu499
    1. da S D. C.. Chaba et al., “Low bone mineral density among HIV-infected patients in Brazil,” Rev. Inst. Med. Trop. São Paulo, vol. 59, p. e89, 2017, 10.1590/S1678-9946201759089
    1. Assoumou L. et al., “Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.,” AIDS Lond. Engl., vol. 27, no. 15, pp. 2425–2430, September 2013, 10.1097/QAD.0b013e32836378c3
    1. Rivas P., Gorgolas M., Garcia-Gelgado R., Diaz-Curiel M., Goyenechea A., and Fernandez-Guerrero M. L., “Evolution of bone mineral density in AIDS patients on treatment with zidovudine / lamivudine plus abacavir or lopinavir / ritonavir,” HIV Med., vol. 9, pp. 89–95, 2008, 10.1111/j.1468-1293.2007.00525.x
    1. Gomes D. C., Valadares A. L. R., Amaral E., Ferreira N. D. O., and Pinto-neto A. M., “Association between HIV infection and bone mineral density in climacteric women,” Arch. Osteoporos., vol. 10, p. 33, 2015, 10.1007/s11657-015-0238-z
    1. Mondy K. and Tebas P., “Emerging bone problems in patients infected with human immunodeficiency virus,” Clin Infect Dis, vol. 36, no. Suppl 2, pp. S101–5, 2003, 10.1086/367566
    1. Dolan S. E., Huang J. S., Killilea K. M., Sullivan M. P., Aliabadi N., and Grinspoon S., “Reduced bone density in HIV-infected women,” AIDS, vol. 18, no. 3, 2004, [Online]. Available: . 10.1097/00002030-200402200-00014
    1. Hoy J. F. et al., “Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial,” J. Bone Miner. Res., vol. 32, no. 9, pp. 1945–1955, June 2017, 10.1002/jbmr.3183
    1. Brown T. T., McComsey G. A., King M. S., Qaqish R. B., Bernstein B. M., and da Silva B. A., “Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen:,” JAIDS J. Acquir. Immune Defic. Syndr., vol. 51, no. 5, pp. 554–561, August 2009, 10.1097/QAI.0b013e3181adce44
    1. Huang J. S., Hughes M. D., Riddler S. A., Haubrich R. H., and AIDS Clinical Trials Group A5142 Study Team, “Bone Mineral Density Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor Selection from ACTG A5142,” HIV Clin. Trials, vol. 14, no. 5, pp. 224–234, October 2013, 10.1310/hct1405-224
    1. Dave J., Cohen K., Micklesfield L., Maartens G., and Levitt N., “Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.,” PLoS ONE, vol. 10, no. 12, p. e0144286, December 2015, 10.1371/journal.pone.0144286
    1. Moran C. A., Weitzmann M. N., and Ofotokun I., “The protease inhibitors and HIV-associated bone loss,” Curr. Opin. HIV AIDS, vol. 11, no. 3, pp. 333–342, May 2016, 10.1097/COH.0000000000000260
    1. Purdy J. B., Gafni R. I., Reynolds J. C., Zeichner S., and Hazra R., “Decreased Bone Mineral Density with Off-Label Use of Tenofovir in Children and Adolescents Infected with Human Immunodeficiency Virus,” J. Pediatr., vol. 152, no. 4, pp. 582–584, April 2008, 10.1016/j.jpeds.2007.12.020
    1. Mccomsey G. A. et al., “Switch from tenofovir disoproxil fumarate combination to dolutegravir plus rilpivirine improves parameters of bone health:,” AIDS, p. 1, December 2017, 10.1097/QAD.0000000000001300
    1. DeJesus E. et al., “Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment,” AIDS Res. Hum. Retroviruses, vol. 34, no. 4, pp. 337–342, January 2018, 10.1089/AID.2017.0203
    1. Maggiolo F. et al., “Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial,” Lancet HIV, vol. 6, no. 10, pp. e655–e666, October 2019, 10.1016/S2352-3018(19)30195-X
    1. Mirembe B. G. et al., “Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.,” J. Acquir. Immune Defic. Syndr. 1999, vol. 71, no. 3, pp. 287–294, March 2016, 10.1097/QAI.0000000000000858
    1. Mulligan K. et al., “Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial,” Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 61, no. 4, pp. 572–580, August 2015, 10.1093/cid/civ324
    1. Gill U. S. et al., “Factors determining bone mineral density loss in chronic hepatitis B patients: is tenofovir disoproxil fumarate the main culprit?,” Gut, vol. 60, no. Suppl 1, p. A230, April 2011, 10.1136/gut.2011.239301.486
    1. Buti M. and Homs M., “Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B,” Expert Rev. Gastroenterol. Hepatol., vol. 6, no. 4, pp. 413–421, August 2012, 10.1586/egh.12.19
    1. Erlandson K. M. et al., “Bone Mineral Density Declines Twice as Quickly Among HIV-Infected Women Compared With Men:,” JAIDS J. Acquir. Immune Defic. Syndr., vol. 77, no. 3, pp. 288–294, March 2018, 10.1097/QAI.0000000000001591
    1. Orlic Z. C. and Raisz L. G., “Causes of Secondary Osteoporosis,” J. Clin. Densitom., vol. 2, no. 1, pp. 79–92, 1999, 10.1385/jcd:2:1:79
    1. Sharma N., Natung T., Barooah R., and Ahanthem S. S., “Effect of Multiparity and Prolonged Lactation on Bone Mineral Density,” J. Menopausal Med., vol. 22, no. 3, pp. 161–166, December 2016, 10.6118/jmm.2016.22.3.161
    1. Polatti F., Capuzzo E., Viazzo F., Colleoni R., and Klersy C., “Bone mineral changes during and after lactation,” Obstet. Gynecol., vol. 94, no. 1, pp. 52–56, July 1999, 10.1016/s0029-7844(99)00236-7
    1. Cooke-Hubley S., Kirby B., Valcour J., Mugford G., Adachi J., and Kovacs C. S., “Spine bone mineral density increases after 6 months of exclusive lactation, even in women who keep breastfeeding,” Arch. Osteoporos., no. 12, p. 73, December 2017, 10.1007/s11657-017-0368-6
    1. Laskey M. A. and Prentice A., “Bone mineral changes during and after lactation,” Obstet. Gynecol., vol. 94, no. 4, pp. 608–615, October 1999. 10.1016/s0029-7844(99)00369-5
    1. Kalkwarf H. J. and Specker B. L., “Bone mineral loss during lactation and recovery after weaning,” Obstet. Gynecol., vol. 86, no. 1, pp. 26–32, July 1995, 10.1016/0029-7844(95)00083-4
    1. Weitzmann M. N., Ofotokun I., Titanji K., Sharma A., and Yin M. T., “Bone Loss Among Women Living With HIV,” Curr. HIV/AIDS Rep., vol. 13, no. 6, pp. 367–373, December 2016, 10.1007/s11904-016-0336-6
    1. Mori T. et al., “Parity, lactation, bone strength, and 16-year fracture risk in adult women: findings from the Study of Women’s Health Across the Nation (SWAN),” Bone, vol. 73, pp. 160–166, Apr. 2015, 10.1016/j.bone.2014.12.013
    1. Kovacs C. S., “The Skeleton Is a Storehouse of Mineral That Is Plundered During Lactation and (Fully?) Replenished Afterwards,” J. Bone Miner. Res., vol. 32, no. 4, pp. 676–680, February 2017, 10.1002/jbmr.3090
    1. Bjørnerem Å. et al., “Irreversible Deterioration of Cortical and Trabecular Microstructure Associated With Breastfeeding,” J. Bone Miner. Res., vol. 32, no. 4, pp. 681–687, October 2016, 10.1002/jbmr.3018
    1. Matovu F. K., Wattanachanya L., Beksinska M., Pettifor J. M., and Ruxrungtham K., “Bone health and HIV in resource-limited settings: a scoping review,” Curr. Opin. HIV AIDS, vol. 11, no. 3, pp. 306–325, May 2016, 10.1097/COH.0000000000000274
    1. Nabwire F. et al., “Changes in Bone Mineral Density During and After Lactation in Ugandan Women With HIV on Tenofovir-Based Antiretroviral Therapy,” J. Bone Miner. Res., vol. n/a, no. n/a, June 2020, 10.1002/jbmr.4121
    1. Flynn P. M. et al., “Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE),” JAIDS J. Acquir. Immune Defic. Syndr., vol. 77, no. 4, pp. 383–392, April 2018, 10.1097/QAI.0000000000001612
    1. Fowler M. et al., “Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention,” N. Engl. J. Med., vol. 375, no. 18, pp. 1726–1737, November 2016, 10.1056/NEJMoa1511691
    1. T. Taha, “Comparing maternal triple antiretrovirals (mART) and infant nevirapine (iNVP) prophylaxis for the prevention of mother-to-child transmission (MTCT) of HIV during breastfeeding (BF),” presented at the 21st International AIDS Conference (AIDS 2016), Durban, South Africa, Jul. 2016.
    1. Currier J. S. et al., “Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm(3),” PLoS ONE, vol. 12, no. 5, p. e0176009, 2017, 10.1371/journal.pone.0176009
    1. INSIGHT START Study Group, Lundgren J., and Babiker A., “Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection,” N. Engl. J. Med., vol. 373, no. 9, pp. 795–807, July 2015, 10.1056/NEJMoa1506816
    1. F. K. Matovu et al., “Depo-Provera worsens bone loss with TDF-containing ART initiation in young women.,” in Abstract Supplement Oral Abstracts from the 23rd International AIDS Conference, Virtual, Jul. 2020, vol. OAB0105, 10.1002/jia2.25547.
    1. Bedimo R., Rosenblatt L., and Myers J., “Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection,” HIV Clin. Trials, vol. 17, no. 6, pp. 246–266, November 2016, 10.1080/15284336.2016.1243363
    1. Sax P. E. et al., “Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials,” The Lancet, vol. 385, no. 9987, pp. 2606–2615, June 2015, 10.1016/S0140-6736(15)60616-X

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner